Choose a language and wait for the translated text.
The company's shares surged 14.7% following the publication of selected data from the study, and were on track for their best trading day since July 2024 if the gains hold.
Celon Pharma's generic semaglutide drug matches Ozempic in early study | PharmaVoice
